Esmee P. Hoefsmit
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Journal: Cancer immunology, immunotherapy : CII
Published: September 30, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Journal: Journal for immunotherapy of cancer
Published: June 18, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Journal: Cancer immunology, immunotherapy : CII
Published: May 22, 2023
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.
Journal: Cancer research communications
Published: January 31, 2023
Acidity-mediated induction of FoxP3+ regulatory T cells.
Journal: European journal of immunology
Published: November 07, 2022
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.
Journal: Cancer immunology research
Published: June 18, 2022
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.
Journal: Journal for immunotherapy of cancer
Published: April 27, 2022
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
Journal: Cell reports. Medicine
Published: October 22, 2021
Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Journal: Journal for immunotherapy of cancer
Published: November 15, 2020
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 05, 2019
Last Updated: 09/26/2026